JP7635208B2 - Ｂ型肝炎ウイルスワクチン - Google Patents

Ｂ型肝炎ウイルスワクチン Download PDF

Info

Publication number
JP7635208B2
JP7635208B2 JP2022513077A JP2022513077A JP7635208B2 JP 7635208 B2 JP7635208 B2 JP 7635208B2 JP 2022513077 A JP2022513077 A JP 2022513077A JP 2022513077 A JP2022513077 A JP 2022513077A JP 7635208 B2 JP7635208 B2 JP 7635208B2
Authority
JP
Japan
Prior art keywords
hbv
seq
vaccine
antigen
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022513077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545530A (ja
JP2022545530A5 (cg-RX-API-DMAC7.html
Inventor
エリック ブリューニング
ジャネット ダグラス
エミリー マーシャル
カリーナ ユシム
ベッテ コーバー
ジェームズ タイラー
Original Assignee
ブイアイアール バイオテクノロジー インコーポレイテッド
トライアド ナショナル セキュリティ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブイアイアール バイオテクノロジー インコーポレイテッド, トライアド ナショナル セキュリティ リミテッド ライアビリティ カンパニー filed Critical ブイアイアール バイオテクノロジー インコーポレイテッド
Publication of JP2022545530A publication Critical patent/JP2022545530A/ja
Publication of JP2022545530A5 publication Critical patent/JP2022545530A5/ja
Application granted granted Critical
Publication of JP7635208B2 publication Critical patent/JP7635208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022513077A 2019-08-29 2020-08-28 Ｂ型肝炎ウイルスワクチン Active JP7635208B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893546P 2019-08-29 2019-08-29
US62/893,546 2019-08-29
US201962941125P 2019-11-27 2019-11-27
US62/941,125 2019-11-27
PCT/US2020/048411 WO2021045969A1 (en) 2019-08-29 2020-08-28 Hepatitis b virus vaccines

Publications (3)

Publication Number Publication Date
JP2022545530A JP2022545530A (ja) 2022-10-27
JP2022545530A5 JP2022545530A5 (cg-RX-API-DMAC7.html) 2023-08-22
JP7635208B2 true JP7635208B2 (ja) 2025-02-25

Family

ID=74096044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513077A Active JP7635208B2 (ja) 2019-08-29 2020-08-28 Ｂ型肝炎ウイルスワクチン

Country Status (12)

Country Link
US (1) US12485168B2 (cg-RX-API-DMAC7.html)
EP (1) EP4021923A1 (cg-RX-API-DMAC7.html)
JP (1) JP7635208B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220090497A (cg-RX-API-DMAC7.html)
CN (1) CN114729010B (cg-RX-API-DMAC7.html)
AU (1) AU2020342385A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003474A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149415A1 (cg-RX-API-DMAC7.html)
IL (1) IL290924A (cg-RX-API-DMAC7.html)
MX (1) MX2022002270A (cg-RX-API-DMAC7.html)
PH (1) PH12022550490A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021045969A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137016A1 (en) 2001-05-25 2004-07-15 Hong-Mo Moon Pre-S protein of hepatitis B virus (HBV) as an adjuvant and a component of HBV vaccine
US20140106174A1 (en) 2012-10-12 2014-04-17 Hoya Corporation Optical glass, press-molding glass material, optical element and method of manufacturing the same, and bonded optical element
WO2018189522A1 (en) 2017-04-10 2018-10-18 Oxford University Innovation Ltd. Hbv vaccine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86832A (en) 1987-06-22 2002-09-12 Medeva Holdings Bv A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it
DE19904800C1 (de) 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
WO2001027281A1 (en) 1999-10-08 2001-04-19 Celltech Pharma Europe Limited Designing immunogens
ATE320493T1 (de) 2000-06-22 2006-04-15 Ucb Pharma Ltd Modifizierung des hepatitis b kernantigens
US8278432B2 (en) 2002-03-29 2012-10-02 Innogenetics N.V. HBV drug resistance methods
KR101326612B1 (ko) 2003-10-21 2013-11-12 멜버른 헬스 Ｈｂｖ 변이체 검출 및 응용
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
EP2029747A4 (en) 2006-06-06 2011-01-05 Melbourne Health PROOF AND USE OF ANTIVIRAL RESISTANCE MUTATIONS
US20080171062A1 (en) * 2006-08-16 2008-07-17 Monica Sala-Schaeffer Recombinant HBsAg virus-like particles containing polyepitopes of interest, their production and use
CA2770075C (en) * 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
KR101418836B1 (ko) 2012-04-05 2014-08-13 서울대학교산학협력단 간질환 진단용 마커 및 이의 용도
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
LT2964769T (lt) 2013-03-05 2018-12-10 Oregon Health & Science University Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EA201791806A1 (ru) 2015-02-10 2017-12-29 Орегон Хелс Энд Сайенс Юниверсити Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов
EP3402888B1 (en) 2016-01-12 2020-08-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv
WO2018075591A1 (en) * 2016-10-18 2018-04-26 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
CN113950334B (zh) * 2019-06-07 2025-01-28 俄勒冈健康与科学大学 乙型肝炎病毒特异性t细胞应答

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137016A1 (en) 2001-05-25 2004-07-15 Hong-Mo Moon Pre-S protein of hepatitis B virus (HBV) as an adjuvant and a component of HBV vaccine
US20140106174A1 (en) 2012-10-12 2014-04-17 Hoya Corporation Optical glass, press-molding glass material, optical element and method of manufacturing the same, and bonded optical element
WO2018189522A1 (en) 2017-04-10 2018-10-18 Oxford University Innovation Ltd. Hbv vaccine

Also Published As

Publication number Publication date
AU2020342385A1 (en) 2022-03-31
US12485168B2 (en) 2025-12-02
JP2022545530A (ja) 2022-10-27
US20220288195A1 (en) 2022-09-15
IL290924A (en) 2022-04-01
EP4021923A1 (en) 2022-07-06
MX2022002270A (es) 2022-03-22
CN114729010B (zh) 2025-02-28
CA3149415A1 (en) 2021-03-11
WO2021045969A1 (en) 2021-03-11
BR112022003474A2 (pt) 2022-05-24
KR20220090497A (ko) 2022-06-29
PH12022550490A1 (en) 2023-02-06
CN114729010A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
JP7777907B2 (ja) Ｂ型肝炎ウイルスに対するワクチン
AU2021218141B2 (en) HIV vaccines comprising one or more population episensus antigens
EA012037B1 (ru) Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
CN112552379B (zh) 合成肽在制备防治新型冠状病毒感染药物中的用途
US12485168B2 (en) Hepatitis B virus vaccines
HK40074198A (en) Hepatitis b virus vaccines
HK1241309B (en) Hiv vaccines comprising one or more population episensus antigens
HK1241309A1 (en) Hiv vaccines comprising one or more population episensus antigens
BR122021016789B1 (pt) Vacinas contra hiv-1 compreendendo um ou mais antígenos epissenso de população, usos das mesmas para proteger um indivíduo de uma infecção por hiv-1, tratar hiv-1 e induzir uma resposta de células t de memória efetoras, bem como polipeptídeo e método para projetar e produzir as ditas vacinas
BR112017006865B1 (pt) Vacina contra hiv-1 compreendendo um ou mais antígenos epissenso de população, uso da mesma para proteger um indivíduo de uma infecção por hiv-1 ou para tratar hiv-1 e polipeptídeo
EA040402B1 (ru) Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) антигенов для популяции

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230814

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250212

R150 Certificate of patent or registration of utility model

Ref document number: 7635208

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150